Stryker (NYSE: SYK ) reported earnings on April 17. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Stryker beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share increased significantly.
Gross margins contracted, operating margins dropped, net margins grew.
Stryker reported revenue of $2.16 billion. The 22 analysts polled by S&P Capital IQ predicted revenue of $2.12 billion on the same basis. GAAP reported sales were 7.2% higher than the prior-year quarter's $2.02 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.99. The 26 earnings estimates compiled by S&P Capital IQ predicted $0.99 per share on the same basis. GAAP EPS of $0.91 for Q1 were 17% higher than the prior-year quarter's $0.78 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.2%, 130 basis points worse than the prior-year quarter. Operating margin was 22.7%, 160 basis points worse than the prior-year quarter. Net margin was 16.2%, 90 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $2.13 billion. On the bottom line, the average EPS estimate is $0.99.
Next year's average estimate for revenue is $8.69 billion. The average EPS estimate is $4.11.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,448 members out of 1,478 rating the stock outperform, and 30 members rating it underperform. Among 433 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 424 give Stryker a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stryker is outperform, with an average price target of $61.02.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Stryker the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.